At Henry Ford Hospital in Detroit, Michigan, Dr. Haythem Y Ali—a specialist in Internal Medicine and Breast Medical Oncology—highlights how recent breakthroughs in surgery, radiotherapy, genomic testing, and precision therapies are enabling more personalized breast cancer treatment strategies.
According to Dr. Ali, breast cancer treatment has traditionally been very aggressive, but the approach is changing, with a focus on “right treatment, right dose, right duration for the right patient.”
De-escalation of Treatment
Dr. Ali explains that de-escalation of treatment, or “intensity optimization,” is about matching therapy to risk level and the likelihood of responding to a certain therapy, based on prognostic and predictive assessments.
This approach allows for simpler regimens with fewer side effects for patients with early-stage breast cancer who are at low risk of recurrence and unlikely to benefit from more aggressive treatment.
Dr. Ali notes that breast-conserving surgery has been equivalent to mastectomy in terms of survival since the mid-1980s, and advances in imaging and tumor biology are helping physicians decide how extensive surgery really needs to be.
Advances in Imaging and Tumor Biology
Advances in imaging, such as digital mammography and MRI, have improved the detection and diagnosis of breast cancer, reducing false-positive and false-negative rates.
The understanding of tumor biology has also advanced, with a greater understanding of how cancer cells interact with the body and the role of the immune system and other factors.
Dr. Ali explains that genomic testing allows for a better understanding of the inner workings of a tumor, which can inform treatment decisions and help determine whether a patient genuinely needs chemotherapy after surgery.
For hormone receptor-positive early breast cancer, newer targeted treatments are changing the approach for patients at higher risk of recurrence, by overcoming resistance mechanisms and blocking the cancer’s escape paths.
Dr. Ali notes that doctors balance reducing treatment with the risk of undertreating the cancer by considering multiple factors, including tumor characteristics, patient comorbidity, and patient opinion.
The multidisciplinary breast team plays a key role in deciding which treatments can safely be reduced or avoided, and Dr. Ali emphasizes the importance of coordination between different disciplines to ensure effective care.
According to Dr. Ali, the future of breast cancer treatment is precision medicine, with the goal of providing “right treatment, right amount, right duration” for each patient, and minimizing unnecessary treatment.
One key aspect of this approach is the use of genomic tests and tumor biomarkers to determine the best course of treatment for each patient, and Dr. Ali notes that this approach is already being used to reduce the use of radiotherapy and chemotherapy in some cases.
Refining Axillary Management
Recent data indicate that not all early-stage patients require sentinel lymph-node biopsy. Studies have identified specific tumor and clinical features that allow clinicians to rely on physical examination and imaging alone.
Evidence from these investigations supports omitting surgical node assessment when the disease appears low-risk, thereby sparing patients an additional procedure.
The specialist notes that this shift reduces operative time and postoperative discomfort without compromising oncologic safety.
Patients who avoid axillary surgery also experience fewer complications such as lymphedema, which can impact long-term quality of life.
Imaging Advances and the Tumor Ecosystem
In many centers, tomographic imaging techniques now complement digital mammography and MRI, providing layered views that improve lesion localization.
Ultrasound continues to play a role in differentiating cystic from solid masses, further decreasing false-positive findings.
The oncologist explains that a deeper grasp of the tumor’s surrounding environment, including microbial communities, has reshaped treatment planning.
“It’s sort of like popping the hood of a car to see if the engine is the factory engine or has been altered,” the specialist explained, illustrating how genomic insight reveals hidden aggressiveness.
Such insight guides decisions about chemotherapy, allowing clinicians to forgo systemic therapy when genetic analysis shows a favorable profile.
Balancing these tools involves what the physician describes as five pillars: morphologic assessment, pathological review, genomic data, patient comorbidities, and individual preferences.
